Glioblastoma Multiforme in Patients with Human Immunodeficiency Virus: an Integrated Review and Analysis

Overview

Journal J Neurooncol

Publisher Springer

Date 2022 Jul 20

PMID 35857248

Authors

Mynor J Mendez Valdez

Victor M Lu

Enoch Kim

Sarah R Rivas

Vaidya Govindarajan

Michael Ivan

Ricardo Komotar

Avindra Nath

John D Heiss

Ashish H Shah

Affiliations

Soon will be listed here.

Abstract

Introduction: As lifespans for persons living with HIV (PLWH) have improved over the last decade, there has been a simultaneous increase in non-AIDS-related cancer in that group. However, there is a paucity of data regarding the incidence of glioblastoma multiforme (GBM) in PLWH. Better understanding of the oncogenesis, natural history, and treatment outcomes of GBM in PLWH should lead to improved treatment strategies.

Methods: We performed a comprehensive literature search of six electronic databases to identify eligible cases of GBM among PLWH. Kaplan-Meier estimates, Fisher's exact test, and logistic regression were used to interrogate the data. Epidemiologic data on global HIV prevalence was obtained from the 2016 UNAIDS incidence report, and CNS cancer incidence was obtained from the GDB 2016 Brain and Other CNS Cancer Collaborators.

Results: There is an inverse relationship between the incidence of HIV and CNS cancer globally. Median overall survival (OS) from GBM diagnosis was 8 months. Estimates for survival at 1 and 2 years were 28 and 5%, respectively. There were no statistically significant predictors of OS in this setting. There was a significant difference (p < 0.01) in OS in PLWH and GBM when compared to TCGA age matched cohorts.

Conclusion: The diagnosis of GBM in PLWH is severely underreported in the literature. Despite maximal treatment, OS in this patient population is significantly less than in HIV-negative people. There was a poor prognosis of GBM in PLWH, which is inconsistent with previous reports. Further investigation is required for PLWH and concomitant GBM. Analyses must consider if HAART is maintained in PLWH during GBM treatment.

Citing Articles

Pembrolizumab in an HIV-infected patient with glioblastoma.

Yuen C, Bao S, Pekmezci M, Mo F, Kong X Immunotherapy. 2024; 16(12):803-811.

PMID: 38889068 PMC: 11457652. DOI: 10.1080/1750743X.2024.2362566.

Clinical characteristics and prognostic analysis of patients with HIV and glioma: A case series and literature review.

Ding X, Liang T, Liang B, Zhou X, Chen J, Gao H Exp Ther Med. 2024; 27(2):90.

PMID: 38274346 PMC: 10809446. DOI: 10.3892/etm.2024.12380.

Human endogenous retrovirus K contributes to a stem cell niche in glioblastoma.

Shah A, Rivas S, Doucet-OHare T, Govindarajan V, DeMarino C, Wang T J Clin Invest. 2023; 133(13).

PMID: 37395282 PMC: 10313366. DOI: 10.1172/JCI167929.

References

Hernandez-Ramirez R, Shiels M, Dubrow R, Engels E . Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017; 4(11):e495-e504. PMC: 5669995. DOI: 10.1016/S2352-3018(17)30125-X. View

Shmakova A, Germini D, Vassetzky Y . HIV-1, HAART and cancer: A complex relationship. Int J Cancer. 2019; 146(10):2666-2679. DOI: 10.1002/ijc.32730. View

Ji Y, Lu H . Malignancies in HIV-Infected and AIDS Patients. Adv Exp Med Biol. 2017; 1018:167-179. DOI: 10.1007/978-981-10-5765-6_10. View

Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, ONeill B . A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?. Br J Radiol. 2012; 85(1017):e729-33. PMC: 3487092. DOI: 10.1259/bjr/83796755. View

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Onal H, Mertsoylu H . Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. J Neurosurg Sci. 2010; 54(1):7-19. View

Chaudhry N, Shah A, Ferraro N, Snelling B, Bregy A, Madhavan K . Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest. 2013; 31(5):287-308. DOI: 10.3109/07357907.2013.789899. View

Blumenthal D, Raizer J, Rosenblum M, Bilsky M, Hariharan S, Abrey L . Primary intracranial neoplasms in patients with HIV. Neurology. 1999; 52(8):1648-51. DOI: 10.1212/wnl.52.8.1648. View

Jokonya L, Musara A, Esene I, Kabulo K, Kabeya C, Kaluile Ntenga Kalangu K . Prevalence of human immunodeficiency virus infection in brain glioma patients: Is the virus protective from gliomas?. Surg Neurol Int. 2018; 9:103. PMC: 5991276. DOI: 10.4103/sni.sni_423_17. View

Choy W, Lagman C, Lee S, Bui T, Safaee M, Yang I . Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme. Brain Tumor Res Treat. 2016; 4(2):77-86. PMC: 5114196. DOI: 10.14791/btrt.2016.4.2.77. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

11.

Robbins H, Pfeiffer R, Shiels M, Li J, Hall H, Engels E . Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015; 107(4). PMC: 4334816. DOI: 10.1093/jnci/dju503. View

12.

Hart B, Nordell A, Okulicz J, Palfreeman A, Horban A, Kedem E . Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It?. J Acquir Immune Defic Syndr. 2017; 77(1):1-7. PMC: 5720921. DOI: 10.1097/QAI.0000000000001554. View

13.

Coghill A, Engels E, Schymura M, Mahale P, Shiels M . Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States. J Natl Cancer Inst. 2018; 110(9):959-966. PMC: 6136931. DOI: 10.1093/jnci/djy010. View

14.

Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C . HIV. Lancet. 2018; 392(10148):685-697. DOI: 10.1016/S0140-6736(18)31311-4. View

15.

Lutgen V, Narasipura S, Barbian H, Richards M, Wallace J, Razmpour R . HIV infects astrocytes in vivo and egresses from the brain to the periphery. PLoS Pathog. 2020; 16(6):e1008381. PMC: 7289344. DOI: 10.1371/journal.ppat.1008381. View

16.

Moulignier A, Mikol J, Pialoux G, Eliaszewicz M, Thurel C, Thiebaut J . Cerebral glial tumors and human immunodeficiency virus-1 infection. More than a coincidental association. Cancer. 1994; 74(2):686-92. DOI: 10.1002/1097-0142(19940715)74:2<686::aid-cncr2820740222>3.0.co;2-k. View

17.

Vincendeau M, Kramer S, Hadian K, Rothenaigner I, Bell J, Hauck S . Control of HIV replication in astrocytes by a family of highly conserved host proteins with a common Rev-interacting domain (Risp). AIDS. 2010; 24(16):2433-42. DOI: 10.1097/QAD.0b013e32833e8758. View

18.

Caccuri F, Giagulli C, Bugatti A, Benetti A, Alessandri G, Ribatti D . HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A. 2012; 109(36):14580-5. PMC: 3437870. DOI: 10.1073/pnas.1206605109. View

19.

Sharma I, Singh A, Siraj F, Saxena S . IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma. J Biomed Sci. 2018; 25(1):62. PMC: 6081798. DOI: 10.1186/s12929-018-0464-y. View

20.

Scheidegger P, Weiglhofer W, Suarez S, Console S, Waltenberger J, Pepper M . Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. Biochem J. 2001; 353(Pt 3):569-78. PMC: 1221603. DOI: 10.1042/0264-6021:3530569. View